Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Schizophrenia

  Free Subscription


Articles published in J Clin Psychopharmacol

Retrieve available abstracts of 65 articles:
HTML format



Single Articles


    November 2022
  1. KIM K, Kim YS, Joo EJ, Kim EJ, et al
    Clozapine Blood Concentration Predicts Corrected QT-Interval Prolongation in Patients With Psychoses.
    J Clin Psychopharmacol. 2022;42:536-543.
    PubMed     Abstract available


  2. CONTRUCCI RR, Heikens M, Beex-Oosterhuis MM
    Case Report: Blepharospasms After the Use of Long-Acting Paliperidone Injections.
    J Clin Psychopharmacol. 2022;42:608-609.
    PubMed    


    October 2022
  3. DING J, Zhang Y, Zhang Y, Yang L, et al
    Effects of Age, Sex, and Comedication on the Plasma Concentrations of Olanzapine in Chinese Patients With Schizophrenia Based on Therapeutic Drug Monitoring Data.
    J Clin Psychopharmacol. 2022 Oct 25. pii: 00004714-990000000-00067.
    PubMed     Abstract available


  4. JU V, Walkerly A, VandenBerg A, Shobassy A, et al
    New Onset of Seizures and Psychosis in a Patient Who Is Coprescribed Atomoxetine and Bupropion: A Case Report.
    J Clin Psychopharmacol. 2022 Oct 4. pii: 00004714-990000000-00056.
    PubMed    


  5. OKADA T, Hori H, Hasegawa N, Murata A, et al
    Second-Generation Antipsychotic Monotherapy Contributes to the Discontinuation of Anticholinergic Drugs in Hospitalized Patients With Schizophrenia.
    J Clin Psychopharmacol. 2022 Oct 4. pii: 00004714-990000000-00057.
    PubMed    


  6. DARWISH M, Bugarski-Kirola D, Passarell J, Owen J, et al
    Pimavanserin Exposure-Response Analyses in Patients With Schizophrenia: Results From the Phase 2 ADVANCE Study.
    J Clin Psychopharmacol. 2022 Oct 3. pii: 00004714-990000000-00053.
    PubMed     Abstract available


    September 2022
  7. TEODORO T, Nogueira V, Aldeias J, Teles Martins M, et al
    Clozapine Associated Periorbital Edema in First Episode Psychosis: A Case Report of a Rare Adverse Effect in Treatment-Resistant Schizophrenia.
    J Clin Psychopharmacol. 2022 Sep 5. pii: 00004714-990000000-00049.
    PubMed    


  8. HORIKOSHI S, Miura I, Mui A, Hikichi T, et al
    Second-Generation Antipsychotic Long-Acting Injection Reduced the Time of Restrictive Interventions in Patients With Schizophrenia: Retrospective, A 4-Year Mirror-Image Study.
    J Clin Psychopharmacol. 2022 Sep 5. pii: 00004714-990000000-00048.
    PubMed     Abstract available


  9. KANE JM
    A New Treatment Paradigm: Targeting Trace Amine-Associated Receptor 1 (TAAR1) in Schizophrenia.
    J Clin Psychopharmacol. 2022;42.
    PubMed     Abstract available


  10. SATODIYA RM, Brown VR, Njuguna SW, Bied AM, et al
    A Systematic Review of Clinical Trials on Lumateperone and Its Effects on Body Weight.
    J Clin Psychopharmacol. 2022;42:495-499.
    PubMed     Abstract available


    August 2022
  11. ZHAND N, Labelle A, Ghanem D, Gujral P, et al
    Comparison of Extrapyramidal Symptoms Among Outpatients With Schizophrenia on Long-Acting Injectable Antipsychotics.
    J Clin Psychopharmacol. 2022 Aug 17. pii: 00004714-990000000-00044.
    PubMed     Abstract available


    July 2022
  12. TIEN Y, Huang SC
    Aripiprazole-Associated Acute Dystonia During Dose Reduction in Patient With Schizophrenia and Dementia: A Case Report.
    J Clin Psychopharmacol. 2022 Jul 2. pii: 00004714-990000000-00031.
    PubMed    


  13. GROVER S, Naskar C, Chakrabarti S
    Factors Associated With Poor Response to Clozapine in Schizophrenia: A Study From Northern India.
    J Clin Psychopharmacol. 2022;42:345-349.
    PubMed     Abstract available


  14. GONZALEZ-RODRIGUEZ A, Monreal JA
    Time for Rational Pharmacotherapy in Delusional Disorder: New Targets for Old Clinical Observations.
    J Clin Psychopharmacol. 2022;42:413-414.
    PubMed    


  15. BECHARD L, Morasse-Begis M, Corbeil O, Hakim JR, et al
    Clozapine Rechallenge or Continuation Despite Neutropenia, an Extended Follow-up of a Consecutive Quebec Case Series.
    J Clin Psychopharmacol. 2022;42:391-395.
    PubMed     Abstract available


    June 2022
  16. KOGURE M, Kanahara N, Kimura M, Hanaoka S, et al
    Long-Term Treatment With Long-Acting Injectable Antipsychotic in Schizophrenia Patients With and Without Dopamine Supersensitivity Psychosis: A 6-Year Retrospective Comparative Study.
    J Clin Psychopharmacol. 2022 Jun 17. pii: 00004714-990000000-00026.
    PubMed     Abstract available


  17. CHIU CC, Lin C, Chen WY, Chen CR, et al
    Therapeutic Drug Monitoring of Paliperidone in Patients With Schizophrenia in Taiwan.
    J Clin Psychopharmacol. 2022 Jun 14. pii: 00004714-990000000-00023.
    PubMed     Abstract available


  18. WANG D, Wei N, Hu F, Li J, et al
    Paliperidone Extended Release Versus Olanzapine in Treatment-Resistant Schizophrenia: A Randomized, Double-Blind, Multicenter Study.
    J Clin Psychopharmacol. 2022 Jun 10. pii: 00004714-990000000-00019.
    PubMed     Abstract available


    May 2022
  19. GALLAGHER KE, Funaro MC, Woods SW
    Prescription Stimulants and the Risk of Psychosis: A Systematic Review of Observational Studies.
    J Clin Psychopharmacol. 2022;42:308-314.
    PubMed     Abstract available


    March 2022
  20. YEE CS, Bahji A, Lolich M, Vazquez GH, et al
    Comparative Efficacy and Tolerability of Antipsychotics for Juvenile Psychotic Disorders: A Systematic Review and Network Meta-Analysis.
    J Clin Psychopharmacol. 2022;42:198-208.
    PubMed     Abstract available


  21. FRANKENBURG FR, Malvesti S
    Paliperidone and Edema.
    J Clin Psychopharmacol. 2022;42:225-226.
    PubMed    


    February 2022
  22. TAKAKI M, Yada Y, Sakamoto S, Fujiwara M, et al
    A Decrease of Neutrophils After COVID-19 Vaccination in a Treatment-Resistant Patient With Schizophrenia Taking Clozapine.
    J Clin Psychopharmacol. 2022 Feb 10. pii: 00004714-900000000-98207.
    PubMed    


    January 2022
  23. WANG XY, Chan HY, Lin CH
    Time to Rehospitalization for Different Oral Risperidone Dosing Frequencies in Patients With Schizophrenia: A 17-Year Retrospective Cohort Study.
    J Clin Psychopharmacol. 2022 Jan 6. pii: 00004714-900000000-98219.
    PubMed     Abstract available


  24. CINTRON PASTRANA MA, Quintana Aviles E
    Treatment of Refractory Schizophrenia With Clozapine in a Patient With Wolff-Parkinson-White Syndrome.
    J Clin Psychopharmacol. 2022;42:95-96.
    PubMed    


  25. HE L, Yu Y, Zhang L, He S, et al
    A Real-World Study of Risk Factors for QTc Prolongation in Schizophrenia Patients Receiving Atypical Antipsychotics.
    J Clin Psychopharmacol. 2022;42:71-74.
    PubMed     Abstract available


  26. SMITH RL, Wollmann BM, Kylleso L, Tran TTA, et al
    Effect of Valproic Acid on the Metabolic Spectrum of Clozapine in Patients With Schizophrenia.
    J Clin Psychopharmacol. 2022;42:43-50.
    PubMed     Abstract available


  27. STROMME MF, Mellesdal LS, Bartz-Johannesen CA, Kroken RA, et al
    Use of Benzodiazepines and Antipsychotic Drugs Are Inversely Associated With Acute Readmission Risk in Schizophrenia.
    J Clin Psychopharmacol. 2022;42:37-42.
    PubMed     Abstract available


  28. GARRIGA M, Mallorqui A, Bernad S, Ruiz-Cortes V, et al
    Antipsychotic-Associated Weight Gain and Clinical Improvement Under Clozapine Treatment.
    J Clin Psychopharmacol. 2022;42:75-80.
    PubMed     Abstract available


  29. BONNET U, Knierim U, Ronge R, Jahn J, et al
    Late-Onset Polyserositis Emerging During Long-Term Clozapine Treatment and Persisting After Clozapine Discontinuation: Is Clozapine Really Innocent?
    J Clin Psychopharmacol. 2022;42:106-107.
    PubMed    


  30. ERDOGAN A, Ilhan F
    Risperidone-Associated Acute Laryngeal Dystonia: A Case Report.
    J Clin Psychopharmacol. 2022;42:98-99.
    PubMed    


    November 2021
  31. MAURI MC, Franco G, Minutillo A, Paletta S, et al
    The Switch From Paliperidone Long-Acting Injectable 1- to 3-Monthly: Clinical Pharmacokinetic Evaluation in Patients With Schizophrenia (Preliminary Data).
    J Clin Psychopharmacol. 2021 Nov 24. pii: 00004714-900000000-98229.
    PubMed     Abstract available


  32. RUDA D, Jensen KG, Decara MS, Klauber DG, et al
    CYP2D6 Genotyping and Antipsychotic-Associated Extrapyramidal Adverse Effects in a Randomized Trial of Aripiprazole Versus Quetiapine Extended Release in Children and Adolescents, Aged 12-17 Years, With First Episode Psychosis.
    J Clin Psychopharmacol. 2021;41:667-672.
    PubMed     Abstract available


  33. WEIZMAN S, Shelef A, Bloemhof Bris E, Stryjer R, et al
    A Double-Blind, Placebo-Controlled Trial of Bupropion Add-on to Olanzapine or Risperidone in Overweight Individuals With Schizophrenia.
    J Clin Psychopharmacol. 2021;41:629-631.
    PubMed     Abstract available


  34. COMAI S, Fuamba Y, Rivolta MC, Gobbi G, et al
    Lifetime Cannabis Use Disorder Is Not Associated With Lifetime Impulsive Behavior and Severe Violence in Patients With Schizophrenia Spectrum Disorders From a High-Security Hospital.
    J Clin Psychopharmacol. 2021;41:623-628.
    PubMed     Abstract available


  35. MAKHLOUF AT, Van Alphen MU, Manzano GS, Freudenreich O, et al
    A Seizure After COVID-19 Vaccination in a Patient on Clozapine.
    J Clin Psychopharmacol. 2021;41:689-690.
    PubMed    


  36. CELLINI L, De Donatis D, Mercolini L, Panariello F, et al
    Switch to 3-Month Long-Acting Injectable Paliperidone May Decrease Plasma Levels: A Case Series.
    J Clin Psychopharmacol. 2021;41:694-696.
    PubMed    


  37. OKEYA K, Misawa F, Fujii Y, Takeuchi H, et al
    Olanzapine Reduction From High Dose to Standard Dose: A Retrospective Chart Review.
    J Clin Psychopharmacol. 2021;41:676-680.
    PubMed     Abstract available


  38. SELCUK M
    Tardive Myoclonus Responsive to Clozapine Misdiagnosed as Restless Leg Syndrome: A Case Report.
    J Clin Psychopharmacol. 2021;41:692-694.
    PubMed    


    September 2021
  39. SRIFUENGFUNG M, Sukakul T, Pummangura C, Srifuengfung S, et al
    Oral Ulcers as an Unpredictable Adverse Reaction to Quetiapine Use in a Patient With Schizophrenia.
    J Clin Psychopharmacol. 2021 Sep 9. pii: 00004714-900000000-98247.
    PubMed    


  40. MASHIMA Y, Uchida H, Kinoshita S, Arita Y, et al
    Camptocormia Secondary to Antipsychotic-Associated Dystonia of the Rectus Abdominis Muscles Detected by Abdominal Computed Tomography: A Case Report.
    J Clin Psychopharmacol. 2021;41:608-610.
    PubMed    


  41. CUOMO A, Chioccioli M, Cattaneo CI, Magnani PA, et al
    Effectiveness of Intramuscular Chlorpromazine for Rapid Treatment of Psychomotor Agitation: A Naturalistic, Retrospective, and Observational Study.
    J Clin Psychopharmacol. 2021;41:613-614.
    PubMed    


    August 2021
  42. PEITL V, Badzim VA, Sisko Markos I, Rendulic A, et al
    Improvements of Frontotemporal Cerebral Blood Flow and Cognitive Functioning in Patients With First Episode of Schizophrenia Treated With Long-Acting Aripiprazole.
    J Clin Psychopharmacol. 2021 Aug 26. pii: 00004714-900000000-98248.
    PubMed     Abstract available


  43. OGAWA T, Tachikawa H, Shiratori Y, Sodeyama N, et al
    Use of Blonanserin Transdermal Patch in Home Treatment of Schizophrenia: A Case Study.
    J Clin Psychopharmacol. 2021 Aug 23. pii: 00004714-900000000-98251.
    PubMed    


  44. LIM M, Li Z, Xie H, Tan BL, et al
    The Effect of Therapeutic Alliance on Attitudes Toward Psychiatric Medications in Schizophrenia.
    J Clin Psychopharmacol. 2021 Aug 13. pii: 00004714-900000000-98260.
    PubMed     Abstract available


    July 2021

  45. Association of Aripiprazole With Reduced Hippocampal Atrophy During Maintenance Treatment of First-Episode Schizophrenia: Erratum.
    J Clin Psychopharmacol. 2021;41:507.
    PubMed    


  46. AFTAB R, Pereira M, Hewitt J, Whale R, et al
    Effectiveness and Predictors of Discontinuation of Aripiprazole Long-acting Injection: A 12-Month Naturalistic Cohort Study.
    J Clin Psychopharmacol. 2021;41:478-483.
    PubMed     Abstract available


  47. GLICK ID, Cerfolio NE, Kamis D, Laurence M, et al
    Domestic Mass Shooters: The Association With Unmedicated and Untreated Psychiatric Illness.
    J Clin Psychopharmacol. 2021;41:366-369.
    PubMed     Abstract available


  48. SINKEVICIUTE I, Hugdahl K, Bartz-Johannessen C, Kroken RA, et al
    Differential Effectiveness of Atypical Antipsychotics on Hallucinations: A Pragmatic Randomized Controlled Trial.
    J Clin Psychopharmacol. 2021;41:389-396.
    PubMed     Abstract available


  49. SUHAS S, Manchegowda S, Venkatasubramanian G, Kumar V, et al
    Clozapine and Oral Contraceptives-Implications Beyond Pharmacokinetics: A Case Report.
    J Clin Psychopharmacol. 2021;41:487-490.
    PubMed    


    June 2021
  50. KOREKI A, Mori H, Nozaki S, Koizumi T, et al
    Risk of Nonalcoholic Fatty Liver Disease in Patients With Schizophrenia Treated With Antipsychotic Drugs: A Cross-sectional Study.
    J Clin Psychopharmacol. 2021 Jun 4. pii: 00004714-900000000-98299.
    PubMed     Abstract available


    May 2021
  51. SUHAS S, Shivani S, Singh GK, Venkatasubramanian G, et al
    Festina Lente: Betahistine for Clozapine-Associated Weight Gain: A Case Report.
    J Clin Psychopharmacol. 2021;41:332-333.
    PubMed    


  52. SUZUKI K, Castelli M, Komaroff M, Starling B, et al
    Pharmacokinetic Profile of the Asenapine Transdermal System (HP-3070).
    J Clin Psychopharmacol. 2021;41:286-294.
    PubMed     Abstract available


  53. MATHUR R, Singh J, Sood M
    A Case Report of Clozapine-Associated Stuttering and Amisulpride-Associated Stuttering and Seizure in an Adult on Concurrent Fluoxetine Therapy.
    J Clin Psychopharmacol. 2021;41:330-332.
    PubMed    


  54. TIRUPATI S, Gordon T
    Continuation of Treatment With Clozapine After an Episode of Neutropenia.
    J Clin Psychopharmacol. 2021;41:320-322.
    PubMed     Abstract available


    April 2021
  55. GUIMARAES TM, Guimaraes MRC, Oliveira IAF, Leoni RF, et al
    Mononitrate Isosorbide as an Adjunctive Therapy in Schizophrenia: A Randomized Controlled Crossover Trial.
    J Clin Psychopharmacol. 2021 Apr 14. pii: 00004714-900000000-98311.
    PubMed     Abstract available


  56. LINDENMAYER JP, Rizvi S
    Augmentation With Pimavanserin in Treatment Refractory Schizophrenia: Case Report.
    J Clin Psychopharmacol. 2021 Apr 13. pii: 00004714-900000000-98312.
    PubMed    


    March 2021
  57. AN H, Fan H, Chen S, Qi S, et al
    Effects of Dose, Age, Sex, Body Weight, and Smoking on Plasma Concentrations of Olanzapine and N-desmethyl Olanzapine in Inpatients With Schizophrenia.
    J Clin Psychopharmacol. 2021 Mar 31. pii: 00004714-900000000-98320.
    PubMed     Abstract available


  58. WANG J, Hart KL, Qi W, Ardekani BA, et al
    Association of Aripiprazole With Reduced Hippocampal Atrophy During Maintenance Treatment of First-Episode Schizophrenia.
    J Clin Psychopharmacol. 2021 Mar 31. pii: 00004714-900000000-98319.
    PubMed     Abstract available


  59. REHIMINI S, Goddard KG, Margolese HC
    Exceptionally High Clozapine-Associated Eosinophilia.
    J Clin Psychopharmacol. 2021;41:216-218.
    PubMed    


  60. GROVER S, Naskar C, Chakrabarti S
    Does the Starting of Clozapine Influence Coprescription of Other Medications?: A Study From India.
    J Clin Psychopharmacol. 2021;41:148-154.
    PubMed     Abstract available


  61. GRIFFIN JM, Woznica E, Gilotra NA, Nucifora FC Jr, et al
    Clozapine-Associated Myocarditis: A Protocol for Monitoring Upon Clozapine Initiation and Recommendations for How to Conduct a Clozapine Rechallenge.
    J Clin Psychopharmacol. 2021;41:180-185.
    PubMed     Abstract available


  62. YILDIZ MI, Karacam Dogan M, Mutlu E, Abdullayeva L, et al
    All in One: Clozapine-Associated Acute Pancreatitis With Multiple Organ Involvement.
    J Clin Psychopharmacol. 2021;41:214-216.
    PubMed    


  63. KHURRAM SK, Ames M, Muniz J
    Case Report: Valbenazine as a Treatment for Tardive Dyskinesia and Unexpected Antipsychotic Effects.
    J Clin Psychopharmacol. 2021;41:220-221.
    PubMed    


  64. MISAWA F, Fujii Y, Takeuchi H
    Can a 4-Month Tolerability Assessment With Paliperidone Palmitate 1-Monthly Prevent Neuroleptic Malignant Syndrome Associated With the 3-Monthly?: Analysis Based on a Spontaneous Reporting System Database in Japan.
    J Clin Psychopharmacol. 2021;41:206-207.
    PubMed    


  65. DANILEWITZ M, Rafizadeh R, Bousman CA
    Successful Clozapine Rechallenge After Suspected Clozapine-Associated Myocarditis: A Case Report.
    J Clin Psychopharmacol. 2021;41:218-220.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Schizophrenia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: